Featured in Everyday Health, the NYITCOM doctor shares guidance on common mistakes people make with the new oral GLP-1 medications.
Recap by typeshit. Post by @nyitcomdo on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
HealthDay reports from EASD that the oral GLP-1 showed cardiovascular safety comparable to daily insulin glargine shots in a trial presented Oct. 14, 2026.
Dr Wong says the rare vision loss linked to Ozempic is a small risk, and goes over who may be more vulnerable and which eye changes need care right away.
Loading…